Compare SFST & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | IPSC |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 441.9M |
| IPO Year | 2012 | 2021 |
| Metric | SFST | IPSC |
|---|---|---|
| Price | $60.69 | $2.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $64.00 | $4.25 |
| AVG Volume (30 Days) | 104.6K | ★ 902.3K |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 91.30 |
| EPS | ★ 1.19 | N/A |
| Revenue | $6,282,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | $50.18 | ★ N/A |
| Revenue Growth | 12.99 | ★ 1556.76 |
| 52 Week Low | $34.93 | $0.44 |
| 52 Week High | $62.00 | $2.97 |
| Indicator | SFST | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 48.41 |
| Support Level | $53.96 | $2.13 |
| Resistance Level | $61.53 | $2.45 |
| Average True Range (ATR) | 1.71 | 0.16 |
| MACD | 0.33 | -0.01 |
| Stochastic Oscillator | 85.08 | 43.12 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.